Despite high cost, improved pneumococcal vaccine expected to return 10-year net savings of $12 billion

Health Affairs

Volumn 34, Issue 7, 2015, Pages 1234-1240

  Kohli, Michele A ^a   Farkouh, Raymond A ^b   Maschio, Michael J ^a   McGarry, Lisa J ^a,c   Strutton, David R ^d   Weinstein, Milton C ^e  

^a OPTUM   (United States)

^b Pfizer Vaccines   (United States)

^c ARIAD PHARMACEUTICALS INC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; VACCINE;

ARTICLE; BUDGET; CHILD; CONTROLLED STUDY; COST CONTROL; DRUG COST; HEALTH CARE SYSTEM; HUMAN; INFANT; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PRIVATE HEALTH INSURANCE; PUBLIC HEALTH INSURANCE; VACCINATION; COST BENEFIT ANALYSIS; ECONOMICS; IMMUNOLOGY; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; STREPTOCOCCUS PNEUMONIAE;

CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84936951666     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.1274     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children-United States, 1990-1998. MMWR Morb MortalWkly Rep. 1999;48(12):243-8.
2. Sheridan C. Vaccine market boosters. Nat Biotechnol. 2009;27(6):499-501.
3. Frieden TR. Advisory Committee on Immunization Practices summary report: February 23-24, 2011 [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2011 [cited 2015 May 5]. p. 15-17. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/min-archive/min-feb11.pdf
4. Pollack A. Gilead's hepatitis C drug, Sovaldi, is on pace to become a blockbuster. New York Times. 2014 Jul 23.
5. HHS.gov/HealthCare. The Affordable Care Act and immunization [Internet]. Washington (DC): Department of Health and Human Services; [last updated 2012 Jan 20; cited 2015 May 5]. Available from:http://www.hhs.gov/healthcare/facts/factsheets/2010/09/The-Affordable-Care-Act-and-Immunization.html
6. Centers for Disease Control and Prevention. Vaccines for Children program (VFC) [Internet]. Atlanta (GA): CDC; [last updated 2014 Apr 24; cited 2015 May 5]. Available from: http://www.cdc.gov/vaccines/programs/vfc/index.html
7. Hannan C, Buchanan AD, Monroe J. Maintaining the vaccine safety net. Pediatrics. 2009;124(Suppl 5):S571-2.
8. To repeal the Prevention and Public Health Fund. H.R. 1099. 113th Cong., 1st Sess. (2013).
9. Advisory Committee on Immunization Practices. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2000; 49(RR-9):1-35.
10. Centers for Disease Control and Prevention. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep. 2010;59(9):258-61.
11. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. MMWR Morb Mortal Wkly Rep. 2005;54(36):893-7.
12. Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32-41.
13. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med. 2013;369(2):155-63.
14. Rubin JL, McGarry LJ, Strutton DR, Klugman KP, Pelton SI, Gilmore KE, et al. Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine. 2010;28(48):7634-43.
15. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19-35 months-United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(36):733-40.
16. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Costeffectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J. 2006;25(6):494-501.
17. Martin JA, Hamilton BE, Ventura SJ, Osterman MJ, Mathews TJ. Births:final data for 2011. Natl Vital Stat Rep. 2013;62(1):1-69, 72.
18. Census Bureau. Current Population Survey (CPS): CPS table creator [Internet]. Washington (DC): Census Bureau; [cited 2015 May 5]. Available from: http://www.census.gov/cps/data/cpstablecreator.html#
19. Institute of Medicine. Care without coverage: too little, too late. Washington (DC): National Academies Press; 2002.
20. Institute of Medicine. America's health care safety net: intact but endangered. Washington (DC): National Academies Press; 2000.
21. Ross JS, Bernheim SM, Lin Z, Drye EE, Chen J, Normand S-LT, et al. Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal. Health Aff (Millwood). 2012;31(8):1739-48.
22. Kim L, Gierke R, Lewis M, Link-Gelles R, Farley MM, Schaffer W, et al. Indirect effects of 13-valent pneumococcal conjugate vaccine on invasive pneumococcal pneumonia in adults. Oral abstract presented at:Annual IDWeek of the Infectious Diseases Society of America; 2013, Oct 4; San Francisco, CA.
23. Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population- based surveillance. Lancet Infect Dis. 2015;15(3):301-9.
24. Stockmann C, Byington CL. PCV13 in the USA: early successes and potential challenges. Lancet Infect Dis. 2015;15(3):254-6.
25. Tomczyk S, Bennett NM, Stoecker C, Gierke R, Moore MR, Whitney CG, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years:recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822-5.
26. Williams WW, Lu PJ, O'Halloran A, Bridges CB, Pilishvili T, Hales CM, et al. Noninfluenza vaccination coverage among adults-United States, 2012. MMWR Morb Mortal Wkly Rep. 2014;63(5):95-102.
27. O'Leary ST, Allison MA, Lindley MC, Crane LA, Hurley LP, Brtnikova M, et al. Vaccine financing from the perspective of primary care physicians. Pediatrics. 2014;133(3):367-4.
28. Rosenthal E. The price of prevention:vaccine costs are soaring. New York Times. 2014 Jul 2.
29. McGarry LJ, Krishnarajah G, Hill G, Masseria C, Skornicki M, Pruttivarasin N, et al. Costeffectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: a dynamic model of disease transmission. PLoS One. 2014;9(1):e72723.